A Study to Evaluate the Efficacy and Safety of MIN-117 in Adult Patients With Major Depressive Disorder
Status:
Completed
Trial end date:
2019-12-13
Target enrollment:
Participant gender:
Summary
MIN-117C03 is a 6-week, 3-arm, randomized, double-blind, placebo controlled study to
investigate the safety and efficacy of MIN-117 in male and female patients with Major
Depressive Disorder, aged 18 to 65 years. Approximately 324 patients were to be randomly
assigned to 1 of 3 treatment arms, including placebo, 2.5 mg MIN-117, or 5.0 mg MIN-117, in a
2:1:1 ratio.